XM does not provide services to residents of the United States of America.
S
S

Straumann

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Swiss stocks - Factors to watch on May 2

Swiss stocks - Factors to watch on May 2 ZURICH/BERLIN, May 2 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Thursday: CREDIT SUISSE South Korea's financial authorities have notified Credit Suisse AG it could face 50 billion won ($36.32 million) in fines over allegations it breached short-selling rules, South Korea's Chosun Ilbo daily reported on Thursday, citing industry sources.
A
C
L
S
S
U

Adidas, HSBC, Renishaw

EUROPE RESEARCH ROUNDUP-Adidas, HSBC, Renishaw May 1 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Adidas, HSBC and Renishaw on Wednesday. HIGHLIGHTS * Adidas AG ADSGn.DE : Wedbush raises target price to EUR 233 from EUR 200 * Darktrace DARK.L : HSBC raises target price to 620p from 540p * Essity AB (Publ) ESSITYb.ST : HSBC resumes with buy rating; price target SEK 330 * HSBC HSBA.L : Berenberg raises target price to 830p from 80
A
A
A
A
B
B
B
C
C
E
E
F
F
H
H
H
K
L
M
P
R
S
S
S
T
E
G
N
S
U

Dental implant maker Straumann slumps on softer U.S. performance

CORRECTED-BUZZ-Dental implant maker Straumann slumps on softer U.S. performance Corrects name and brokerage of the analyst in 2nd and 4th bullets ** Swiss implant maker Straumann STMN.S slumps around 9% after softer performance in North America, its second largest region, overshadows strong Q1 growth in Asia Pacific ** Q1 North America revenues fell 2.3%, which Stifel Europe analyst Daniel Jelovcan says may have taken many by surprise, as most U.S.
S

Dental implants maker Straumann sales boosted by strong Asia Pacific

UPDATE 2-Straumann shares slip on slowing US dental implant demand Shares down 10.5% at 1046 GMT Organic growth slows in N.America and EMEA CEO says high interest rates hit US patient traffic Q1 organic sales growth 15.1%, with 82% jump in APAC Recasts with share reaction, CEO comments in paragraphs 2-4 By Mateusz Dobrzyniewski and Marleen Kaesebier April 30 (Reuters) - Shares in Swiss dental implants maker Straumann STMN.S fell more than 10% on Tuesday, as slower U.S.
S

Dental implants maker Straumann posts 15% organic sales growth for Q1

Dental implants maker Straumann posts 15% organic sales growth for Q1 April 30 (Reuters) - Swiss dental implants maker Straumann STMN.S reported 15.1% organic sales growth for the first quarter on Tuesday, driven by high demand for its premium implants across its markets. The company, which specialises in tooth replacement and orthodontic solutions, reported revenue of 643.8 million Swiss francs ($706.5 million) in the first three months of 2024, up from 596 million francs a year earlier.
S

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.